We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Barnes Group (B) Withdraws Guidance on Coronavirus Concerns
Read MoreHide Full Article
Barnes Group, Inc. (B - Free Report) has withdrawn its earlier announced guidance for 2020 on end-market uncertainties due to the coronavirus pandemic.
Also, the company announced that its commercial activities have been continuing at reduced levels due to the pandemic. However, it remains committed to protect the safety, health and well-being of employees, customers, and partners amid the crisis.
Guidance Withdrawn
On the fourth-quarter 2019 conference call held in February, Barnes Group had anticipated adjusted earnings of $3.12-$3.32 per share for 2020.
For the year, the company had expected organic sales growth of 1-3%, while operating margin was estimated to be 16-17%. Also, the company’s capital expenditure was projected to be $60 million.
However, on uncertainties regarding the impacts of the outbreak on financial and operating results, the company has now withdrawn its guidance for 2020. Notably, the duration of the coronavirus pandemic, its geographic spread and the impacts of the governmental regulations imposed in response to the crisis will likely have a bearing on Barnes Group’s results.
Bottom Line
The COVID-19 pandemic has dealt a further blow to the manufacturing sector, which was already reeling under the U.S.-China trade tensions and weak global demand. Factory closures across the globe, supply-chain disruptions, low demand for goods and the impacts of the restrictions imposed by several governments, among others, have affected the sector.
Zacks Rank, Price Performance and Estimate Trend
Barnes Group, with a $1.8-billion market capitalization, currently carries a Zacks Rank #4 (Sell).
Over the past three months, the company’s share price has decreased 44% compared with the industry’s decline of 29.5%.
In the past 30 days, the Zacks Consensus Estimate for its earnings has been lowered by 8.5% to $2.89 for 2020 and by 4.5% to $3.37 for 2021.
Tennant delivered a positive earnings surprise of 26.60%, on average, in the trailing four quarters.
Broadwind Energy delivered a positive earnings surprise of 10.42%, on average, in the trailing four quarters.
EnPro delivered a positive earnings surprise of 1.98%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Barnes Group (B) Withdraws Guidance on Coronavirus Concerns
Barnes Group, Inc. (B - Free Report) has withdrawn its earlier announced guidance for 2020 on end-market uncertainties due to the coronavirus pandemic.
Also, the company announced that its commercial activities have been continuing at reduced levels due to the pandemic. However, it remains committed to protect the safety, health and well-being of employees, customers, and partners amid the crisis.
Guidance Withdrawn
On the fourth-quarter 2019 conference call held in February, Barnes Group had anticipated adjusted earnings of $3.12-$3.32 per share for 2020.
For the year, the company had expected organic sales growth of 1-3%, while operating margin was estimated to be 16-17%. Also, the company’s capital expenditure was projected to be $60 million.
However, on uncertainties regarding the impacts of the outbreak on financial and operating results, the company has now withdrawn its guidance for 2020. Notably, the duration of the coronavirus pandemic, its geographic spread and the impacts of the governmental regulations imposed in response to the crisis will likely have a bearing on Barnes Group’s results.
Bottom Line
The COVID-19 pandemic has dealt a further blow to the manufacturing sector, which was already reeling under the U.S.-China trade tensions and weak global demand. Factory closures across the globe, supply-chain disruptions, low demand for goods and the impacts of the restrictions imposed by several governments, among others, have affected the sector.
Zacks Rank, Price Performance and Estimate Trend
Barnes Group, with a $1.8-billion market capitalization, currently carries a Zacks Rank #4 (Sell).
Over the past three months, the company’s share price has decreased 44% compared with the industry’s decline of 29.5%.
In the past 30 days, the Zacks Consensus Estimate for its earnings has been lowered by 8.5% to $2.89 for 2020 and by 4.5% to $3.37 for 2021.
Stocks to Consider
Some better-ranked stocks from the same space are Tennant Company (TNC - Free Report) Broadwind Energy, Inc. (BWEN - Free Report) and EnPro Industries (NPO - Free Report) . While Tennant currently sports a Zacks Rank #1 (Strong Buy), Broadwind Energy and EnPro carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Tennant delivered a positive earnings surprise of 26.60%, on average, in the trailing four quarters.
Broadwind Energy delivered a positive earnings surprise of 10.42%, on average, in the trailing four quarters.
EnPro delivered a positive earnings surprise of 1.98%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>